Authors: Abraham, E Laterre, PF Garbino, J Pingleton, S Butler, T Dugernier, T Margolis, B Kudsk, K Zimmerli, W Anderson, P Reynaert, M Lew, D Lesslauer, W Passe, S Cooper, P Burdeska, A Modi, M Leighton, A Salgo, M Van der Auwera, P

Citation: E. Abraham et al., Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients, CRIT CARE M, 29(3), 2001, pp. 503-510

Authors: Moyle, G Pozniak, A Opravil, M Clumeck, N DelFraissy, JF Johnson, M Pelgrom, J Reynes, J Vittecoq, D DeLora, P Salgo, M Duff, F

Citation: G. Moyle et al., The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues, J ACQ IMM D, 23(2), 2000, pp. 128-137

Authors: Stellbrink, HJ Hawkins, DA Clumeck, N Cooper, DA Myers, R Delfraissy, JF Gill, MJ Ramirez-Ronda, C Vella, S Salgo, M Bragman, K

Citation: Hj. Stellbrink et al., Randomised, multicentre phase III study of saquinavir plus zidovudine pluszalcitabine in previously untreated or minimally pretreated HIV-infected patients, CLIN DRUG I, 20(5), 2000, pp. 295-307

Authors: Babiker, A Bartlett, J Breckenridge, A Collins, G Coombs, R Cooper, D Creagh, T Cross, A Daniels, M Darbyshire, J Dawson, D DeGruttola, V DeMasi, R Dolin, R Eron, J Fischl, M Grossberg, S Hamilton, J Hammer, S Hartigan, P Henry, K Hill, A Hughes, M Kahn, J Katlama, C Katzenstein, D Kim, S Mildvan, D Montaner, J Moore, M Neaton, J O'Brien, W Ribaudo, H Richman, D Saag, M Salgo, M Saravolatz, L Schooley, R Seligmann, M Staszewski, S Struthers, L Tierney, C Tsiatis, A Welles, S

Citation: A. Babiker et al., Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis, AIDS RES H, 16(12), 2000, pp. 1123-1133

Authors: Abrams, D Allan, D Antunes, F Breckenridge, A Bruun, J Cameron, W Carbon, C Chalmers, I Chang, H Chodakewitz, J Clendenin, N Clumeck, N Collier, A Collins, G Cooper, E Cooper, D Danner, S D'Aquila, R DeGruttola, V DeMasi, R Dee, L Deyton, L Dixon, D Farthing, C Feinberg, J Fischl, M Flepp, M Gartland, M Gatell, J Gazzard, B Goebel, F Gotzsche, P Gringeri, A Hall, D Hamilton, J Hammer, S Hartigan, P Heath-Chiozzi, M Henry, K Hill, A Hirschel, B Ioannidis, J Kahn, J Katlama, C Katzenstein, D Killen, J King, E de Loes, SK Kravcik, S Lange, J Leavitt, R Leonard, J Maeland, A Mannucci, P Mathiesen, L McDade, H Meibohn, A Melander, H Merigan, T Mulder, J Myers, M Neaton, J Nessling, M Perrin, L Pettinelli, C Phair, J Phillips, A Pinching, A Poppa, A Power, L Reiss, P Richman, D Rooney, J Rousseau, F Rutherford, G Salgo, M Sandstrom, E Saravolatz, L Savidge, G Schnittman, S Schooley, R Seligmann, M Simberkoff, M Skowron, G Slade, P Smith, D Smith, RP Soriano, V Stanley, K Stingl, G Stoffels, P Struthers, L Tierney, C Thompson, M Van der Broeck, R Van Leeuven, R Van Weverling, G Veenstra, J Vella, S Volberding, P Weber, J Winslow, D Yeni, P Yeo, J Dormont, J Sande, M Weller, I Babiker, A Collins, R Darbyshire, J Duncan, W Foulkes, M Hughes, M Peto, R Peto, T Walker, S

Citation: D. Abrams et al., Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence, LANCET, 353(9169), 1999, pp. 2014-2025